One of their programs displays stretches of DNA in a three-dimensional color format that a customer can use, for example, to pinpoint the genetic differences between healthy and cancerous prostatetissue.
Texas pathology group ProPath stopped getting prostatetissue from large urology groups more than four years ago, said executive director Krista Crews, when these clients began doing lab work in-house.
The study found that doctors' practices that do their own lab work bill the federal Medicare program for analyzing 72% more prostatetissue samples per biopsy while detecting fewer cases of cancer than counterparts who send specimens to outside labs.